{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:24:27Z","timestamp":1761920667391,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K11430"],"award-info":[{"award-number":["17K11430"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.01339","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T23:28:25Z","timestamp":1576711705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Pattern Visually Evoked Potentials in Japanese Girl With Optic Neuritis and Seropositive to Anti-myelin Oligodendrocyte Glycoprotein (MOG) Antibody"],"prefix":"10.3389","volume":"10","author":[{"given":"Shunichiro","family":"Takano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Hanabusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Sassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Airi","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhei","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Ohde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1471-4159.1989.tb10930.x","article-title":"Differential ultrastructural localization of myelin basic protein, myelin\/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 30-phosphodiesterase in the CNS of adult rats","volume":"52","author":"Brunner","year":"1989","journal-title":"J Neurochem"},{"key":"B2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanthan","year":"2016","journal-title":"Autoimmune Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti\u2013myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"14","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Probstel","year":"2015","journal-title":"J Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"B10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.braindev.2014.02.002","article-title":"Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a Japanese boy with recurrent optic neuritis","volume":"37","author":"Tsuburaya","year":"2015","journal-title":"Brain Dev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/bmj.4.5893.661","article-title":"Visual evoked response in diagnosis of multiple sclerosis","volume":"4","author":"Halliday","year":"1973","journal-title":"Br Med J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1600-0404.1983.tb04547.x","article-title":"Evoked potentials. With special reference to the diagnostic value in multiple sclerosis","volume":"67","author":"Kjaer","year":"1983","journal-title":"Acta Neurol Scand"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jnnp.40.10.1009","article-title":"Pattern reversal evoked visual potential in the diagnosis of multiple sclerosis","volume":"40","author":"Matthews","year":"1977","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/S0161-6420(99)90342-1","article-title":"Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older","volume":"106","author":"Grover","year":"1999","journal-title":"Ophthalmology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","article-title":"ISCEV standard for clinical visual evoked potentials: (2016 update)","volume":"133","author":"Odom","year":"2016","journal-title":"Doc. Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1212\/WNL.0000000000000636","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"83","author":"Kezuka","year":"2014","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10384-018-0561-1","article-title":"Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis","volume":"62","author":"Kezuka","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/NRL.0000000000000122","article-title":"Recurrent optic neuritis associated with MOG antibody seropositivity","volume":"22","author":"Chang","year":"2017","journal-title":"Neurologist"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.01339\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T10:58:42Z","timestamp":1576753122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.01339\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,19]]},"references-count":21,"alternative-id":["10.3389\/fneur.2019.01339"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.01339","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2019,12,19]]},"article-number":"1339"}}